Cameron’s Law
- Sponsor
- Rep. Gottheimer, Josh [D-NJ-5]
- Committees
- Ways and Means Committee (primary)
- Last action
- Feb 18, 2025
Bottom line
"Cameron's Law" doubles the orphan drug tax credit to encourage the development of treatments for rare diseases, potentially increasing federal tax expenditures.
What it actually does
This bill, known as "Cameron's Law," amends the Internal Revenue Code of 1986 to increase the orphan drug tax credit from 25 percent to 50 percent of qualified clinical testing expenses. This change effectively restores the credit to its pre-2017 level, aiming to incentivize pharmaceutical companies to develop treatments for rare diseases.
Proponents argue
Supporters argue that restoring the orphan drug tax credit to 50 percent is crucial for incentivizing pharmaceutical research and development into treatments for rare diseases, which often affect small patient populations and thus offer limited commercial returns. They contend that this tax credit helps offset the high costs and risks associated with developing these specialized drugs, ultimately bringing life-saving or life-improving therapies to patients who currently have few or no options.
Opponents contend
Critics might argue that increasing the orphan drug tax credit to 50 percent represents a significant tax expenditure that disproportionately benefits large pharmaceutical companies, potentially without sufficient accountability for drug pricing or actual research outcomes. They may contend that such a generous credit could lead to "evergreening" of existing drugs or focus on conditions that are not truly rare, diverting resources from other public health priorities or increasing the national debt.
The bill text is extremely short and straightforward, making it very accessible for any reader to understand its direct legislative impact.
Section 2(a)
Restoration of Orphan Drug Tax Credit Amount
This section directly amends Section 45C(a) of the Internal Revenue Code of 1986. It changes the percentage of qualified clinical testing expenses that can be claimed as an orphan drug tax credit from 25 percent to 50 percent. This effectively reverses a change made by the Tax Cuts and Jobs Act of 2017, returning the credit to its original, higher value to provide a greater financial incentive for drug development for rare diseases.
Supporters argue
Supporters argue that this restoration is vital to ensure that pharmaceutical companies continue to invest in the challenging and often unprofitable field of orphan drug development. They emphasize that the higher credit is necessary to offset the substantial costs and risks, ensuring that patients with rare diseases, who often have no other treatment options, receive the attention and resources needed for new therapies.
Critics contend
Opponents might contend that the 50 percent credit is overly generous and could lead to inefficient allocation of resources, potentially subsidizing research that would occur anyway or encouraging the development of drugs with marginal benefits at significant taxpayer expense. They may also point to the potential for abuse or high drug prices even with the credit.
Tradeoffs
The provision balances the desire to incentivize life-saving drug development for rare diseases against the cost to federal tax revenue and concerns about the efficiency and oversight of such tax expenditures. There is a tension between supporting innovation for underserved populations and ensuring fiscal responsibility and fair market practices in the pharmaceutical industry.